Actinium, Heron planning follow-ons
Late Tuesday, Actinium Pharmaceuticals Inc. (NYSE-M:ATNM) and Heron Therapeutics Inc. (NASDAQ:HRTX) proposed follow-ons, but neither company disclosed how many shares they plan to issue or how much they expect to raise. Actinium's follow-on is underwritten by Canaccord Genuity and Laidlaw, while Heron's offering is underwritten by Jefferies and Leerink Partners.
Actinium's Actimab-A, actinium-225 attached to the anti- CD33 mAb lintuzumab (HuM195), is in Phase I/II testing to treat acute myelogenous leukemia (AML). The company's Iomab-B, an anti- CD45 mAb (BC8) labeled with iodine-131, has completed Phase II testing and is in development as a bone marrow conditioning agent for use prior to hematopoietic stem cell transplant in patients with relapsed or refractory AML. ...